P. Morris

C. Hudis, S. Cremers, P. Morris, 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

S. Larson, C. Hudis, P. Morris, 2010, Clinical breast cancer.

Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.

S. Larson, C. Hudis, P. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan.

P. Morris, M. Heinemann, D. Ilson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

E. Winer, C. Hudis, L. Norton, 2011, Clinical Cancer Research.

Therapeutic challenges in primary CNS lymphoma

P. Morris, L. Abrey, 2009, The Lancet Neurology.

A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”.

P. Morris, B. Hennessy, J. Crown, 2018 .

Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland

P. Morris, C. Kelly, Martina Smith, 2020, Cancers.

Patterns of participation of patients in cancer clinical trials in Ireland

P. Morris, O. Breathnach, D. Kehily, 2007, Irish journal of medical science.

Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.

P. Morris, K. Cadoo, M. Fornier, 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Patient demographics and management challenges in an Irish symptomatic breast cancer unit

P. Morris, B. Hennessy, O. Breathnach, 2020, Irish Journal of Medical Science (1971 -).

Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment— questions from the KRISTINE study

P. Morris, J. Gleeson, N. Keegan, 2018 .

Microtubule Active Agents: Beyond the Taxane Frontier

P. Morris, M. Fornier, 2008, Clinical Cancer Research.

Post‐transplant malignancy in solid organ transplant recipients in Ireland, The Irish Transplant Cancer Group

P. Morris, J. Egan, D. Little, 2019, Clinical transplantation.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

D. Correa, L. Deangelis, P. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How can clinical research help our understanding of trastuzumab-related cardiotoxicity?

P. Morris, T. Lyons, 2015, EBioMedicine.

Copper-64 trastuzumab PET imaging: a reproducibility study.

J. Humm, S. Larson, C. Hudis, 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

P. Morris, A. Linehan, O. Fitzpatrick, 2021, Breast cancer.

Personalizing therapy for metastatic breast cancer

C. Hudis, P. Morris, 2009, Expert review of anticancer therapy.

Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial.

P. Morris, M. Hennessy, 2020, Annals of palliative medicine.

Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)

P. Morris, B. Hennessy, N. McElvaney, 2020, Thorax.

The impact of outpatient systemic anti-cancer treatment on patient costs and work practices

P. Morris, B. Hennessy, O. Breathnach, 2017, Irish Journal of Medical Science (1971 -).

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

P. Morris, O. Breathnach, L. Grogan, 2020, BMC cancer.

Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern

P. Morris, O. Breathnach, H. Humphreys, 2008, Supportive Care in Cancer.

Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma

P. Morris, A. Lassman, 2010, Nature Reviews Clinical Oncology.

Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?

P. Morris, M. Hennessy, 2019, Anti-cancer drugs.

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

E. Winer, Zhou Zhu, P. Morris, 2020, Clinical Cancer Research.

Identifying the challenges of biomarkers that predict response to HER2-directed therapies

P. Morris, N. Iyengar, 2013, Expert opinion on pharmacotherapy.

Delivery of systemic anti-cancer therapy during the COVID-19 pandemic

P. Morris, B. Hennessy, O. Breathnach, 2021, Irish Journal of Medical Science (1971 -).

Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy

L. Deangelis, P. Morris, A. Omuro, 2011, Leukemia & lymphoma.

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients

P. Morris, P. O'kelly, F. Daly, 2020, Renal failure.

Recent advances in novel targeted therapies for HER2-positive breast cancer

P. Morris, C. Murphy, 2012, Anti-cancer drugs.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

O. Elemento, P. Brown, C. Hudis, 2018, Cancer Prevention Research.

PI3K inhibition to overcome endocrine resistance in breast cancer

Bryan T Hennessy, P. Morris, B. Hennessy, 2018, Expert opinion on investigational drugs.

Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme – Data from a national neuro-oncology registry

P. Morris, W. Mullally, P. O’Halloran, 2022, Journal of Clinical Neuroscience.

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

P. Morris, B. Hennessy, A. Farrelly, 2021, Journal of Translational Medicine.

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

P. Morris, B. Hennessy, S. Furney, 2021, Cancers.

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

S. Chandarlapaty, C. Hudis, L. Norton, 2016, Clinical breast cancer.

Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy

P. Morris, B. Hennessy, O. Breathnach, 2018, Irish Journal of Medical Science (1971 -).

Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas

P. Morris, L. Abrey, 2010, Targeted Oncology.

Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Aaron E. Chiou, C. Hudis, P. Morris, 2019, Biomaterials.

The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme

P. Morris, R. Bambury, 2014, Expert review of anticancer therapy.

Tumour Genome Characterization of a Rare Case of Pulmonary Enteric Adenocarcinoma and Prior Colon Adenocarcinoma

P. Morris, B. Hennessy, S. Furney, 2021, Journal of personalized medicine.

Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis

Bo Ri Seo, Olivier Elemento, Delphine Gourdon, 2015, Science Translational Medicine.

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

B. O'neill, P. Morris, B. Hennessy, 2020, Cancers.

Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.

P. Morris, M. Fornier, Patrick G Morris, 2009, Clinical advances in hematology & oncology : H&O.

White adipose tissue inflammation and cancer‐specific survival in patients with squamous cell carcinoma of the oral tongue

C. Hudis, P. Morris, A. Dannenberg, 2016, Cancer.

Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer

C. Hudis, P. Morris, A. Omuro, 2012, The breast journal.

Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer

C. Hudis, L. Norton, P. Morris, 2018, Clinical Breast Cancer.

Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy

P. Morris, D. Collins, 2015, Expert opinion on pharmacotherapy.

Declining incidence of keratinocyte carcinoma in organ transplant recipients

P. Morris, J. Egan, D. Houlihan, 2019, The British journal of dermatology.

Therapeutic options for metastatic breast cancer

C. Hudis, P. Morris, H. McArthur, 2009, Expert opinion on pharmacotherapy.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

P. Morris, A. Hill, B. Hennessy, 2018, Therapeutic advances in medical oncology.

Dose-dense chemotherapy for breast cancer: what does the future hold?

C. Hudis, L. Norton, P. Morris, 2010, Future oncology.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

E. Winer, P. Morris, H. Rugo, 2021, The Lancet. Oncology.

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

E. Winer, P. Morris, I. C. Tudor, 2017 .

Optimizing the use of anthracyclines in older patients with breast cancer.

P. Morris, M. Fornier, 2011, Critical reviews in oncology/hematology.

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast‐conservation therapy for lymph node‐negative, human epidermal growth factor receptor 2‐positive breast cancer

C. Hudis, P. Morris, H. McArthur, 2012, Cancer.

Novel anti-tubulin cytotoxic agents for breast cancer

P. Morris, M. Fornier, 2009, Expert review of anticancer therapy.

Aromatase inhibitor strategies in metastatic breast cancer

P. Morris, H. McArthur, 2009, International journal of women's health.

Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer

S. Larson, C. Hudis, P. Morris, 2013, Nuclear medicine communications.

Optimizing dose-dense regimens for early-stage breast cancer

C. Hudis, P. Morris, 2010, Nature Reviews Clinical Oncology.

Bone scans, bisphosphonates, and a lack of acute changes within the mandible.

S. Larson, C. Hudis, P. Morris, 2011, Journal of oral and maxillofacial surgery.

Impact of obesity on the survival of patients with early‐stage squamous cell carcinoma of the oral tongue

C. Hudis, P. Morris, A. Dannenberg, 2014, Cancer.

Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy

M. Kris, L. Deangelis, P. Morris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases

D. O'Leary, P. Morris, E. Kay, 2017, Medicine.

P. Morris, B. Hennessy, J. Gleeson, 2019, Cancer medicine.

Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?

P. Morris, 2012, Anti-cancer drugs.

Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.

P. Morris, R. Bambury, 2014, Anti-cancer drugs.

Variation in Nonmelanoma Skin Cancer Incidence by Treatment Modality Among Patients Receiving Multiple Kidney Transplants

P. Morris, J. Egan, P. O'kelly, 2019, JAMA dermatology.

Brain metastases in breast cancer

P. Morris, M. Khasraw, S. Patil, 2014, Expert review of anticancer therapy.

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

E. Winer, C. Hudis, L. Norton, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Hudis, P. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy in the Covid-19 era: the patient’s perception

P. Morris, B. Hennessy, O. Breathnach, 2021, Irish Journal of Medical Science (1971 -).

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer

P. Morris, J. Gleeson, N. Keegan, 2018, Expert opinion on biological therapy.

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy

P. Morris, M. Doherty, 2015, International journal of women's health.

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

C. Hudis, P. Morris, H. McArthur, 2016, Clinical breast cancer.

Advances in therapy: eribulin improves survival for metastatic breast cancer

P. Morris, 2010, Anti-cancer drugs.

Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer

P. Morris, B. Hennessy, O. Breathnach, 2020, Expert opinion on pharmacotherapy.

Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.

C. Hudis, P. Morris, H. McArthur, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

C. Hudis, L. Norton, P. Morris, 2015, Molecular oncology.

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.

P. Morris, L. Tenori, I. Bertini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomineralogical signatures of breast microcalcifications

P. Morris, M. Morrow, L. Estroff, 2023, Science advances.

Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas.

Meredith M. Lee, D. Muller, C. Hudis, 2017, Journal of structural biology.

Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series

P. Morris, M. J. Kennedy, Fionnuala King, 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Lack of familiarity with genetic testing among patients in Ireland with Cancer

P. Morris, W. Mullally, B. Hennessy, 2020, Irish Journal of Medical Science (1971 -).

Obesity, Inflammation, and Breast Cancer

C. Hudis, P. Morris, A. Dannenberg, 2013 .

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.

C. Hudis, L. Norton, P. Morris, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

E. Winer, C. Hudis, L. Norton, 2013, Cancer.

Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

C. Hudis, P. Morris, A. Dannenberg, 2013, Cancer Prevention Research.

Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study.

C. Hudis, L. Norton, P. Morris, 2010 .